Insilico Medicine Doses First Patient in Phase III Trial of AI-Discovered Rentosertib for IPF
Insilico Medicine announced that the first patient has been enrolled and dosed in GENESIS-IPF-3, a Phase III clinical trial of Rentosertib, its AI-driven innovative drug candidate for idiopathic pulmonary fibrosis.
Founded in 2014, Insilico Medicine conducts drug discovery using its Pharma. AI platform and automated laboratories.
Fosun Pharma has entered into a partnership with Insilico Medicine to jointly develop small-molecule innovative drugs.
WuXi AppTec became an early shareholder of Insilico Medicine through venture investment and also serves as its largest CRO/CDMO supplier, undertaking research and development outsourcing work. The two parties are also engaged in joint research and pipeline advancement cooperation in the field of AI drug discovery.
Why this event matters
The event has a measured impact on 3 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 60% confidence over a long term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 50
- Confidence
- 60%
- Horizon
- Long term
Artificial Intelligence
- Direction
- positive
- Intensity
- 45
- Confidence
- 50%
- Horizon
- Long term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 40
- Confidence
- 55%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.